REFERENCES
- US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-in-fected adults and adolescents. February12, 2013. http://aidsinfo.nih.gov/
- European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV-infected adults in Europe. November 2012. http://www.europeanaidsclini-calsociety.org/
- Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2013). http://www.gesida-seimc.org/
- Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medi-cal Association of the Infectious Disease Society of Amer-ica and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–627.
- Orkin C, Dejesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir com-pared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial [published online ahead of print October 23, 2012]. HIV Med. doi: 10.1111/j.1468-1293.2012.01060.x.
- Arast’h K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14:859–864.
- Llibre JM. First line boosted protease inhibitors-based regimens in treatment naïve HIV-infected patients. Making a good thing better. AIDS Rev. 2009;11:215–222.
- McComsey GA, Ward DJ, Hessenthaler SM, et al. Improve-ment in lipoatrophy associated with highly active antiretro-viral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovu-dine: The results of the TARHEEL study. Clin Infect Dis. 2004;38:263–270.
- Martin A, Smith DE, Carr A, et al. Reversibility of lipoatro-phy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS. 2004;18:1029–1036.
- Shlay JC, Visnegarwala F, Bartsch G, et al. Body composi-tion and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147–155.
- Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavu-dine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2007;44:139–147.
- Trottier B, Machouf N, Thomas R, et al. Abacavir/lami-vudine fixed-dose combination with ritonavir boosted darunavir: A safe and efficacious regimen for HIV therapy. HIV Clin Trials. 2012;13:335–342.
- Nishijima T, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S. Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: A pilot study. AIDS. 2012;26:649–651.
- Melial S, Phillips E, Carosi G, et al. HLA-B*5701 screen-ing for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579.
- Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results. J Infect Dis. 2011;204:1191–1201.
- Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus rito-navir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011154: 445–456.
- Ding X, Andraca-Carrera E, Cooper C, et al. No associa-tion of myocardial infarction with ABC use: An FDA meta-analysis [abstract 808]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections (CR01); Febru-ary 27-March 2, 2011; Boston, MA.
- Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myo-cardial infarction and abacavir therapy: No increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20–28.
- Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: A meta-analysis of published and unpublished data. AIDS. 2011;25:1993–2004.
- Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocar-dial infarction associated with initial antiretroviral treatment containing abacavir: Short- and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52:929–940.